Free Trial

Onconetix Q1 2024 Earnings Report

$0.54 +0.01 (+1.89%)
As of 01/21/2025 04:00 PM Eastern

Onconetix EPS Results

Actual EPS
-$6.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Onconetix Revenue Results

Actual Revenue
$0.70 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Onconetix Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Onconetix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Onconetix and other key companies, straight to your email.

About Onconetix

Onconetix (NASDAQ:ONCO), a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

View Onconetix Profile

More Earnings Resources from MarketBeat